Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. decreased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 23.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 4,784,658 shares of the biopharmaceutical company's stock after selling 1,474,260 shares during the period. Franklin Resources Inc. owned 4.56% of Revance Therapeutics worth $24,593,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of RVNC. Certuity LLC purchased a new position in shares of Revance Therapeutics during the 2nd quarter worth $26,000. FORA Capital LLC acquired a new position in Revance Therapeutics in the third quarter valued at $54,000. Creative Planning purchased a new position in Revance Therapeutics during the third quarter worth about $56,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Revance Therapeutics in the 2nd quarter worth about $33,000. Finally, Accredited Investors Inc. acquired a new stake in Revance Therapeutics in the 3rd quarter worth about $67,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on RVNC shares. StockNews.com began coverage on shares of Revance Therapeutics in a report on Friday. They set a "hold" rating on the stock. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating on the stock in a report on Tuesday, December 10th. Needham & Company LLC reissued a "hold" rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright reaffirmed a "neutral" rating and issued a $6.60 target price on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, Barclays reiterated an "equal weight" rating and issued a $7.00 target price (down previously from $10.00) on shares of Revance Therapeutics in a report on Friday, September 13th. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $8.96.

Revance Therapeutics Stock Up 0.7 %

Shares of NASDAQ RVNC traded up $0.02 during trading on Friday, reaching $3.09. 3,458,729 shares of the stock were exchanged, compared to its average volume of 2,819,810. The company has a market capitalization of $322.57 million, a price-to-earnings ratio of -1.60 and a beta of 0.81. The business's 50-day moving average price is $4.38 and its 200 day moving average price is $4.47. Revance Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $9.74.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analysts' expectations of $67.73 million. As a group, sell-side analysts expect that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current fiscal year.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.